دورية أكاديمية
Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).
| العنوان: | Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC). |
|---|---|
| المؤلفون: | Maluf FC; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Beneficência Portuguesa de São Paulo, São Paulo, Brazil.; Latin American Oncology Group (LACOG), Rio Grande do Sul, Brazil., Pereira FMT; Latin American Oncology Group (LACOG), Rio Grande do Sul, Brazil.; Hospital São Camilo, São Paulo, Brazil., Serrano Uson PL Jr; Hospital Israelita Albert Einstein, São Paulo, Brazil., Bastos DA; Latin American Oncology Group (LACOG), Rio Grande do Sul, Brazil.; Hospital Sirio-Libanês, São Paulo, Brazil.; Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, Brazil., Rodrigues da Rosa DA; Latin American Oncology Group (LACOG), Rio Grande do Sul, Brazil.; Grupo Oncoclínicas, Rio de Janeiro, Brazil., Wiermann EG; Latin American Oncology Group (LACOG), Rio Grande do Sul, Brazil.; Instituto de Oncologia do Paraná, Curitiba, Brazil., Schutz FA; Beneficência Portuguesa de São Paulo, São Paulo, Brazil.; Latin American Oncology Group (LACOG), Rio Grande do Sul, Brazil., Kater FR; Beneficência Portuguesa de São Paulo, São Paulo, Brazil.; Latin American Oncology Group (LACOG), Rio Grande do Sul, Brazil., de Oliveira FNG; Latin American Oncology Group (LACOG), Rio Grande do Sul, Brazil.; Clinica CLION/Grupo CAM, Salvador, Bahia., Marques Monteiro FS; Latin American Oncology Group (LACOG), Rio Grande do Sul, Brazil.; Hospital Santa Lucia, Brasília, Brazil.; Hospital Universitário de Brasília, Brasília, Brazil., de Pádua FV; Latin American Oncology Group (LACOG), Rio Grande do Sul, Brazil.; Hospital Sírio Libanês, Brasília, Brazil., Orlandi FJ; Orlandi Oncología, Santiago, Chile., de Almeida Saito HP; Centro de Oncologia Campinas, São Paulo, Brazil., Ayadi M; Institut Salah-Azaïz de Cancerologie, Tunis.; Faculté de Médecine, Tunis, Tunisia., Boghikian PS; Fundacion Arturo Lopez Perez, Santiago, Chile., Kopp RM; Latin American Oncology Group (LACOG), Rio Grande do Sul, Brazil.; Clínica Porto Azul, Barranquilla, Colombia.; Hospital Universitario 12 de Octubre, Madrid, Spain., de Carvalho RS; Beneficência Portuguesa de São Paulo, São Paulo, Brazil.; Latin American Oncology Group (LACOG), Rio Grande do Sul, Brazil., de Fogace RN; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Latin American Oncology Group (LACOG), Rio Grande do Sul, Brazil., de Araújo Cavallero SR; Hospital Ophir Loyol, Belém, Pará, Brazil., Aguiar S; Universidad de la República, Montevideo, Uruguay., Souza VC; Latin American Oncology Group (LACOG), Rio Grande do Sul, Brazil.; Grupo de oncologia D'Or, Rio de Janeiro, Brazil., Sommer SG; Oncology Institute of Southern Switzerland (IOSI), Bellinzona and Università della Svizzera Italiana, Lugano, Switzerland.; Manchester Cancer Research Centre, Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom. |
| المصدر: | JCO global oncology [JCO Glob Oncol] 2021 Apr; Vol. 7, pp. 550-558. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101760170 Publication Model: Print Cited Medium: Internet ISSN: 2687-8941 (Electronic) Linking ISSN: 26878941 NLM ISO Abbreviation: JCO Glob Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Alexandria, VA : American Society of Clinical Oncology, [2020]- |
| مواضيع طبية MeSH: | Androgen Antagonists*/therapeutic use , Prostatic Neoplasms, Castration-Resistant*/drug therapy, Developing Countries ; Docetaxel ; Humans ; Male ; Orchiectomy |
| مستخلص: | Purpose: International guideline recommendations may not always be extrapolated to developing countries where access to resources is limited. In metastatic castration-sensitive prostate cancer (mCSPC), there have been successful drug and imaging advancements that were addressed in the Prostate Cancer Consensus Conference for Developing Countries for best-practice and limited-resource scenarios. Methods: A total of 24 out of 300 questions addressed staging, treatment, and follow-up for patients with mCSPC both in best-practice settings and resource-limited settings. Responses were compiled and presented in percentage of clinicians supporting each response. Questions had 4-8 options for response. Results: Recommendations for staging in mCSPC were split but there was consensus that chest x-ray, abdominal and pelvic computed tomography, and bone scan should be used where resources are limited. In both de novo and relapsed low-volume mCSPC, orchiectomy alone in limited resources was favored and in relapsed high-volume disease, androgen deprivation therapy plus docetaxel in limited resources and androgen deprivation therapy plus abiraterone in high-resource settings were consensus. A 3-weekly regimen of docetaxel was consensus among voters. When using abiraterone, a regimen of 1,000 mg plus prednisone 5 mg/d is optimal, but in limited-resource settings, half the panel agreed that abiraterone 250 mg with fatty foods plus prednisone 5 mg/d is acceptable. The panel recommended against the use of osteoclast-targeted therapy to prevent osseous complications. There was consensus that monitoring of patients undergoing systemic treatment should only be conducted in case of prostate-specific antigen elevation or progression-suggestive symptoms. Conclusion: The treatment recommendations for most topics addressed differed between the best-practice setting and resource-limited setting, accentuating the need for high-quality evidence that contemplates the effect of limited resources on the management of mCSPC. Competing Interests: Fernando Cotait MalufHonoraria: Janssen Oncology, Astellas Pharma, Bayer Schering Pharma, Merck Sharp and Dohme,Roche/Genentech, BMS Brazil, Ipsen, Sanofi/Aventis, Merck Serono, AstraZenecaConsulting or Advisory Role: Janssen Oncology, Astellas Pharma, Bayer Schering Pharma, Merck Sharp and Dohme, Roche/Genentech, BMS Brazil, Ipsen, Merck Serono, AstraZenecaResearch Funding: Janssen-Cilag, Merck Sharp and DohmeTravel, Accommodations, Expenses: Merck Sharp and Dohme, Bayer Schering Pharma Felipe Moraes Toledo PereiraHonoraria: Janssen, Zodiac Pharma, MSD, Libbs, Bayer, AmgenConsulting or Advisory Role: Janssen Diogo Assed BastosHonoraria: MSD, Roche, Bristol-Myers Squibb, Janssen-Cilag, Astellas Pharma, AstraZeneca, BayerConsulting or Advisory Role: Roche, Bayer, Janssen-CilagResearch Funding: Janssen-Cilag, Pfizer, Astellas PharmaTravel, Accommodations, Expenses: Janssen-Cilag, Bayer Diogo Augusto Rodrigues da RosaHonoraria: RocheConsulting or Advisory Role: Janssen-Cilag, Bristol-Myers Squibb, AstraZeneca, Astellas PharmaSpeakers' Bureau: AstraZeneca, Dr. Reddy's Laboratories, Roche, MSD Oncology, BMS BrazilTravel, Accommodations, Expenses: Janssen-Cilag, Roche, BMS Brazil, Ipsen Evanius Garcia WiermannConsulting or Advisory Role: Janssen OncologySpeakers' Bureau: BayerTravel, Accommodations, Expenses: Bayer Schering Pharma Fábio A. SchutzEmployment: IpsenConsulting or Advisory Role: Bayer, Janssen Oncology, Roche, Merck Sharp and Dohme, Bristol-Myers Squibb, Pfizer, Astellas Pharma, AstraZenecaSpeakers' Bureau: Janssen Oncology, Astellas Pharma, Bayer, Pfizer, Bristol-Myers Squibb, AstraZeneca, Merck Sharp and Dohme, RocheResearch Funding: Janssen OncologyTravel, Accommodations, Expenses: Merck Sharp and Dohme, Roche, Bristol-Myers Squibb, Astellas Pharma, Janssen-Cilag Fábio Roberto KaterConsulting or Advisory Role: Janssen-Cilag, PfizerTravel, Accommodations, Expenses: Janssen-Cilag Fernando Nunes Galvão de OliveiraConsulting or Advisory Role: Janssen OncologySpeakers' Bureau: Janssen Oncology, Astellas Pharma, MSD OncologyTravel, Accommodations, Expenses: Astellas Pharma, MSD Oncology Fernando Sabino Marques MonteiroConsulting or Advisory Role: Bristol-Myers Squibb, Roche, MSD Oncology, JanssenSpeakers' Bureau: Janssen, MSD Oncology, IpsenResearch Funding: JanssenTravel, Accommodations, Expenses: Janssen, Roche, Bristol-Myers Squibb Francisco Javier OrlandiHonoraria: Roche/GenentechConsulting or Advisory Role: AstraZeneca, Roche/Genentech, Bristol-Myers Squibb, MSD Oncology, Lilly, Pfizer, Novartis, SanofiSpeakers' Bureau: AstraZeneca/MedImmune, RocheResearch Funding: AstraZeneca/MedImmune, Amgen, Genentech/Roche, Boehringer Ingelheim, Astellas Medivation, MSD Oncology, Bristol-Myers Squibb, Celltrion, Pfizer, mAbxience, Nektar, Sanofi, Genentech/Roche, AstraZeneca/MedImmune Pamela Salman BoghikianConsulting or Advisory Role: Roche/Genentech, Novartis, Lilly, Merck SeronoSpeakers' Bureau: Roche/Genentech, Novartis, Lilly Ray Manneh KoppHonoraria: Astellas Scientific and Medical Affairs,Inc., Janssen-Cilag, Bayer, Merck Sharp and Dohme, Roche, Bristol-Myers Squibb, Sanofi, AstraZeneca, PfizerConsulting or Advisory Role: Astellas Pharma, Janssen-Cilag, Roche, Merck Serono, Merck Sharp and Dohme, AstraZeneca, Sanofi, PfizerSpeakers' Bureau: San Jorge Foundation, ACHOResearch Funding: Pfizer, Merck Sharp and Dohme, NovartisTravel, Accommodations, Expenses: Merck Sharp and Dohme Rodrigo Nogueira de FogaceTravel, Accommodations, Expenses: Bayer Schering Pharma Sandro Roberto de Araújo CavalleroHonoraria: Astellas Pharma, Janssen Oncology, AstraZenecaConsulting or Advisory Role: Janssen Oncology, Astellas PharmaSpeakers' Bureau: Pfizer, Janssen-Cilag, Astellas PharmaTravel, Accommodations, Expenses: Pfizer, Roche/Genentech, Janssen-Cilag, Astellas Pharma Vinicius Carreira SouzaConsulting or Advisory Role: Janssen, Astellas Pharma, Bayer, BMS BrazilResearch Funding: JanssenTravel, Accommodations, Expenses: Janssen Silke Gillessen SommerConsulting or Advisory Role: Astellas Pharma, Advanced Accelerator Applications, Roche, Janssen, Bayer, Orion Pharma GmbH, Menarini Silicon Biosystems, Tolero Pharmaceuticals, MSD Oncology, Amgen, PfizerSpeakers' Bureau: Janssen-CilagPatents, Royalties, Other Intellectual Property: Method for biomarker (WO 3752009138392 A1)Travel, Accommodations, Expenses: ProteoMedixOther Relationship: ProteoMediX, Aranda PharmaNo other potential conflicts of interest were reported. |
| References: | J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68. (PMID: 12359855) Prostate. 2018 Sep;78(12):889-895. (PMID: 29707790) Lancet. 2011 Mar 5;377(9768):813-22. (PMID: 21353695) N Engl J Med. 2019 Jul 11;381(2):121-131. (PMID: 31157964) JAMA Oncol. 2019 Aug 1;5(8):1159-1167. (PMID: 31246234) Eur Urol Oncol. 2019 Nov;2(6):649-655. (PMID: 31411985) J Urol. 2001 Jan;165(1):104-7. (PMID: 11125375) Einstein (Sao Paulo). 2019 Mar 07;17(2):eGS4414. (PMID: 30843996) Eur Urol. 2018 Feb;73(2):178-211. (PMID: 28655541) N Engl J Med. 2019 Jul 4;381(1):13-24. (PMID: 31150574) Asian Pac J Cancer Prev. 2015;16(3):1259-75. (PMID: 25735366) Eur Urol. 2020 Jan;77(1):38-52. (PMID: 31493960) Lancet. 2016 Mar 19;387(10024):1163-77. (PMID: 26719232) J Natl Cancer Inst. 2004 Jun 2;96(11):879-82. (PMID: 15173273) CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593) J Urol. 2018 May;199(5):1224-1232. (PMID: 29129779) J Clin Oncol. 2014 Apr 10;32(11):1143-50. (PMID: 24590644) Eur Urol Focus. 2017 Dec;3(6):518-521. (PMID: 29500136) CA Cancer J Clin. 2018 Jan;68(1):7-30. (PMID: 29313949) Lancet Oncol. 2013 Feb;14(2):117-24. (PMID: 23294853) Investig Clin Urol. 2020 Feb;61(Suppl 1):S3-S7. (PMID: 32055749) Ann Oncol. 2018 May 1;29(5):1235-1248. (PMID: 29529169) N Engl J Med. 2015 Aug 20;373(8):737-46. (PMID: 26244877) J Clin Oncol. 2008 Mar 1;26(7):1148-59. (PMID: 18309951) N Engl J Med. 2017 Jul 27;377(4):352-360. (PMID: 28578607) Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018 Mar - Apr;37(2):103-109. (PMID: 29422356) |
| المشرفين على المادة: | 0 (Androgen Antagonists) 15H5577CQD (Docetaxel) |
| تواريخ الأحداث: | Date Created: 20210415 Date Completed: 20210805 Latest Revision: 20210805 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC8162577 |
| DOI: | 10.1200/GO.20.00505 |
| PMID: | 33856896 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2687-8941 |
|---|---|
| DOI: | 10.1200/GO.20.00505 |